| 3.19 -0.01 (-0.31%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.34 | 1-year : | 4.94 |
| Resists | First : | 3.72 | Second : | 4.23 |
| Pivot price | 3.25  |
|||
| Supports | First : | 2.9 | Second : | 2.41 |
| MAs | MA(5) : | 3.12  |
MA(20) : | 3.35 |
| MA(100) : | 3.79 |
MA(250) : | 4.14 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 22.8 |
D(3) : | 18 |
| RSI | RSI(14): 42.7 |
|||
| 52-week | High : | 6.51 | Low : | 2.23 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MNKD ] has closed above bottom band by 43.7%. Bollinger Bands are 32% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.2 - 3.22 | 3.22 - 3.23 |
| Low: | 3.05 - 3.07 | 3.07 - 3.08 |
| Close: | 3.16 - 3.19 | 3.19 - 3.21 |
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Fri, 23 Oct 2026
Did Clinical Data On Furoscix ReadyFlow Just Shift MannKind (MNKD) Investment Narrative? - Simply Wall Street
Sat, 29 Aug 2026
MannKind (MNKD) Could Be 48% Undervalued Following Its Afrezza And Pipeline Narrative - Yahoo Finance
Thu, 06 Aug 2026
MannKind Corp (MNKD) (Q2 2026) Earnings Call Highlights: Record Revenue and Major Catalysts ... - Yahoo Finance
Thu, 06 Aug 2026
MannKind Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:MNKD) 2026-08-06 - Seeking Alpha
Thu, 09 Jul 2026
MannKind Corporation (MNKD) Up 20% Since Afrezza FDA Approval - Yahoo Finance
Mon, 29 Jun 2026
Is MannKind Corporation (MNKD) A Good Stock To Buy Now? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 322 (M) |
| Shares Float | 298 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 57.1 (%) |
| Shares Short | 26,160 (K) |
| Shares Short P.Month | 26,550 (K) |
| EPS | -0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.22 |
| Profit Margin | -11.1 % |
| Operating Margin | -0.8 % |
| Return on Assets (ttm) | 0.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 42.9 % |
| Gross Profit (p.s.) | 0.92 |
| Sales Per Share | 1.22 |
| EBITDA (p.s.) | 0.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | 40 (M) |
| PE Ratio | -22.79 |
| PEG Ratio | 4.3 |
| Price to Book value | -14.5 |
| Price to Sales | 2.6 |
| Price to Cash Flow | -127.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|